Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 3
1981 2
1982 2
1984 1
1985 3
1986 5
1987 2
1988 6
1989 2
1990 4
1991 2
1992 7
1993 3
1994 6
1995 4
1996 5
1997 2
1998 6
1999 6
2000 6
2001 10
2002 7
2003 10
2004 5
2005 6
2006 5
2007 7
2008 8
2009 5
2010 5
2011 8
2012 5
2013 12
2014 7
2015 15
2016 15
2017 15
2018 14
2019 11
2020 15
2021 14
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

261 results
Results by year
Filters applied: . Clear all
Page 1
MGMT Status as a Clinical Biomarker in Glioblastoma.
Butler M, Pongor L, Su YT, Xi L, Raffeld M, Quezado M, Trepel J, Aldape K, Pommier Y, Wu J. Butler M, et al. Among authors: trepel j. Trends Cancer. 2020 May;6(5):380-391. doi: 10.1016/j.trecan.2020.02.010. Epub 2020 Mar 27. Trends Cancer. 2020. PMID: 32348734 Free PMC article. Review.
Targeting the dynamic HSP90 complex in cancer.
Trepel J, Mollapour M, Giaccone G, Neckers L. Trepel J, et al. Nat Rev Cancer. 2010 Aug;10(8):537-49. doi: 10.1038/nrc2887. Nat Rev Cancer. 2010. PMID: 20651736 Free PMC article. Review.
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Thomas A, Takahashi N, Rajapakse VN, Zhang X, Sun Y, Ceribelli M, Wilson KM, Zhang Y, Beck E, Sciuto L, Nichols S, Elenbaas B, Puc J, Dahmen H, Zimmermann A, Varonin J, Schultz CW, Kim S, Shimellis H, Desai P, Klumpp-Thomas C, Chen L, Travers J, McKnight C, Michael S, Itkin Z, Lee S, Yuno A, Lee MJ, Redon CE, Kindrick JD, Peer CJ, Wei JS, Aladjem MI, Figg WD, Steinberg SM, Trepel JB, Zenke FT, Pommier Y, Khan J, Thomas CJ. Thomas A, et al. Among authors: trepel jb. Cancer Cell. 2021 Apr 12;39(4):566-579.e7. doi: 10.1016/j.ccell.2021.02.014. Cancer Cell. 2021. PMID: 33848478
Cancer vaccine strategies: translation from mice to human clinical trials.
Berzofsky JA, Terabe M, Trepel JB, Pastan I, Stroncek DF, Morris JC, Wood LV. Berzofsky JA, et al. Among authors: trepel jb. Cancer Immunol Immunother. 2018 Dec;67(12):1863-1869. doi: 10.1007/s00262-017-2084-x. Epub 2017 Nov 15. Cancer Immunol Immunother. 2018. PMID: 29143114 Free PMC article. Review.
Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer.
Roper N, Velez MJ, Chiappori A, Kim YS, Wei JS, Sindiri S, Takahashi N, Mulford D, Kumar S, Ylaya K, Trindade C, Manukyan I, Brown AL, Trepel JB, Lee JM, Hewitt S, Khan J, Thomas A. Roper N, et al. Among authors: trepel jb. Nat Commun. 2021 Jun 23;12(1):3880. doi: 10.1038/s41467-021-24164-y. Nat Commun. 2021. PMID: 34162872 Free PMC article.
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.
Apolo AB, Nadal R, Girardi DM, Niglio SA, Ley L, Cordes LM, Steinberg SM, Sierra Ortiz O, Cadena J, Diaz C, Mallek M, Davarpanah NN, Costello R, Trepel JB, Lee MJ, Merino MJ, Bagheri MH, Monk P, Figg WD, Gulley JL, Agarwal PK, Valera V, Chalfin HJ, Jones J, Streicher H, Wright JJ, Ning YM, Parnes HL, Dahut WL, Bottaro DP, Lara PN Jr, Saraiya B, Pal SK, Stein MN, Mortazavi A. Apolo AB, et al. Among authors: trepel jb. J Clin Oncol. 2020 Nov 1;38(31):3672-3684. doi: 10.1200/JCO.20.01652. Epub 2020 Sep 11. J Clin Oncol. 2020. PMID: 32915679 Free PMC article. Clinical Trial.
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, Lee S, Ling A, Spittler AJ, Carter CA, Guha U, Wang Y, Szabo E, Meltzer P, Steinberg SM, Trepel JB, Loehrer PJ, Giaccone G. Thomas A, et al. Among authors: trepel jb. Lancet Oncol. 2015 Feb;16(2):177-86. doi: 10.1016/S1470-2045(14)71181-7. Epub 2015 Jan 13. Lancet Oncol. 2015. PMID: 25592632 Free PMC article. Clinical Trial.
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marté J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL. Karzai F, et al. Among authors: trepel jb. J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2. J Immunother Cancer. 2018. PMID: 30514390 Free PMC article.
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, Lee JM. Zimmer AS, et al. Among authors: trepel jb. J Immunother Cancer. 2019 Jul 25;7(1):197. doi: 10.1186/s40425-019-0680-3. J Immunother Cancer. 2019. PMID: 31345267 Free PMC article. Clinical Trial.
Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors.
Yuno A, Lee MJ, Lee S, Tomita Y, Rekhtman D, Moore B, Trepel JB. Yuno A, et al. Among authors: trepel jb. Methods Mol Biol. 2018;1709:423-441. doi: 10.1007/978-1-4939-7477-1_29. Methods Mol Biol. 2018. PMID: 29177675 Review.
261 results